Another study from the same group showed that the use of another CTSS inhibitor (RO5461111, IC50 0.4 nM and 0.5 nM toward human and murine CTSS, respectively), a competitive reversible inhibitor [64], with and without the PAR-2 inhibitor, GB83 which inhibits trypsin cleavage of PAR-2, reduced markers of diabetic nephropathy and diabetic retinopathy in type 2 diabetic (db/db) mice [38]. This evidence concerns the gene F2RL1 and diabetic kidney disease.